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Hyperphosphorylated keratin (K) 8 acts as a phosphate “sponge” for stress-activated protein kinases thereby inhibiting pro-
apoptotic molecules and thus apoptosis. MAP kinase/ERK1 has increased activity in colorectal cancer (CRC) and is known
to phosphorylate K8. The aims were to identify the K8 isoforms abundantly present in colon tumors, using 2D diﬀerence gel
electrophoresis (DIGE), to identify the modifications using mass spectrometry, and to validate the diﬀerential abundance of these
isoforms in tumors relative to matched normal mucosae. 2D DIGE showed 3 isoforms of K8 significantly increased in tumor ≥2-
fold in 6/8 pairs. Metal oxide aﬃnity chromatography mass spectrometry and bioinformatics were used to identify phosphorylated
serine residues. Levels of PS24, PS432, and PS74 by western blotting were found to be significantly increased in tumor versus
matched normal. Blocking of EGFR signaling in Caco2 cells showed a significant decrease (P < 0.0001) in K8 PS74 and PS432
levels by 59% and 66%, respectively, resulting in increased apoptosis.
1. Introduction
K8 and K18 are the major intermediate filament (IF)
components of simple epithelia of the gastrointestinal tract,
liver, pancreas, and mammary glands [1]. Cellular K8
interacts with K18 to form insoluble 10 nm filaments that
extend from the nucleus to the internal leaflet of the
plasma membrane, where they interact with desmosomes
and hemidesmosomes to bridge transmembrane domain
proteins via plakins [2]. Increased expression of K8/18 has
been associated with metastasis and invasion in cancer [3–6].
The phosphorylation of IF proteins is of primary importance
in their function, regulating assembly, disassembly, and
organisation in vitro and in vivo [7, 8]. Toivola et al. (1997)
showed that phosphorylation of IF is essential for the correct
function of keratins, and when serine/threonine phosphatase
activity is downregulated, cell junctions and the organisation
of IF and microfilament assembly are disrupted. Increased
phosphorylation of K8/18 results in increased solubilisation
and the inhibition of subunit polymerisation [9]. The K8
residue serine 73 is known to be phosphorylated by c-Jun N-
terminal kinase (JNK) and p38 kinases during cellular stress
[10–12] and serine residue 431 is phosphorylated by ERK1
in response to EGFR stimulation [10, 12, 13]. (Phospho-
serine (PS) 73 is subsequently referred to in this paper
as PS74, similarly PS431 as PS432 and PS23 as PS24, in
accordance with the nomenclature adopted by UniProtKB,
taking into account the first Met.) Increased signaling via
the EGFR pathway has been well documented in CRC
and is due to upregulation of activating ligands such as
EGF, epiregulin, amphiregulin, and TGFα or by activating
mutations in EGFR itself [14]. Constitutive activation of the
RAS/RAF/MEK/ERK pathway occurs in almost 50% of CRC
patients due to mutations in the KRAS and BRAF genes
[15–17]. It is likely therefore that phospho-K8 may be more
abundant in such cases. However, little is known of the
frequency and type of K8 phospho-isoforms in CRC. The
aims of this study were to identify the isoforms of K8 in
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tumors from a 2D DIGE study, to identify the position of the
modifications using mass spectrometry (MS), and to validate
the overabundance of these isoforms in CRC patients’ tumor
relative to matched normal mucosa by western blotting.
Finally, we sought to determine the eﬀect of blocking MAP
kinase activity on the level of K8 phosphorylation and level
of induced apoptosis.
2. Materials and Methods
2.1. Specimens. Tumor and matched adjacent normal muco-
sa specimens, collected from patients undergoing colorectal
tumor resection, were retrieved from a frozen tissue bank
at The Queen Elizabeth Hospital. None of the patients
had received prior chemotherapy or radiotherapy. Ethics
approval was received from the institutional Ethics of Human
Research Committee (protocol 1993/59) and informed con-
sent was obtained in all cases. The work described has been
carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) for
experiments involving humans.
2.2. Antibodies. Antibodies used were K8 (ab9023) at 1 : 500
dilution, K8 PS74 (ab32579), K8 PS432 (ab59434), and β
actin (ab8227) used at 1 : 1000 (all from Abcam, Cambridge,
MA, USA). K8 PS24 (EP1629Y) antibody was used at 1 : 5000
dilutions (Novus Biologicals, Littleton, CO, USA). Cleaved
caspase-3 (Asp175) was used at 1 : 500 (Cell Signalling
Technology, Beverly, MA, USA). Antibodies for β actin (sc-
47778) and EGFR (sc-120) were both used at 1 : 500 (Santa
Cruz, CA, USA). Cy3- (anti-mouse) and Cy5- (anti-rabbit)
labelled secondary antibodies were used at 1 : 1000 (GE
Healthcare, Buckinghamshire, UK).
2.3. Laser Microdissection (LMD) and Protein Extraction.
Malignant glands and normal crypts were enriched using
LMD on matched tumor-normal tissue for 2D DIGE
analysis. We used our previous 2D DIGE pilot data to
calculate the sample size required for statistically significant
diﬀerential expression results using the method described by
Hunt et al. (2005) for gel-based quantitative proteomics [18].
To show a 3-fold diﬀerence in expression, for a power of
90% and P < 0.05, 8 tumor and matched normal samples
were needed. Frozen tissue (all TNM stage II cases) were
embedded in OCT and cryosectioned (30 μm) onto foil-
framed PET membrane slides (Leica, Wetzlar, Germany).
Sections for LMDwere unfixed and unstained while adjacent
sections on glass slides, fixed with 70% ethanol and stained
with haematoxylin, were used for navigation purposes
during LMD (Supplementary Figure 1 will be available at
doi:10.5402/2012/706545). Using the Leica AS LMD6000
system (Leica Microsystems, Wetzlar, Germany), tissue was
microdissected into the cap of a 0.5mL microfuge tube
containing 40 μL of Thiourea/Urea/CHAPS (TUC) buﬀer
(7M Urea, 2M Thiourea, 4% CHAPS, 30mM Tris) with
Halt protease and phosphatase inhibitors (Thermo Fisher
Scientific, Rockford, IL, USA). After solubilisation overnight,
samples were purified using a 2D Clean Up kit (Bio-Rad,
Hercules, CA, USA), quantified using the EZQ protein
assay (Invitrogen, Carlsbad, CA, USA) and diluted with
TUC buffer to 5 μg/μL.
2.4. 2-Dimensional Diﬀerence Gel Electrophoresis (2D DIGE).
2D DIGE was performed according to manufacturer’s pro-
tocol (GE Healthcare). Briefly, protein (50 μg) from each of
the tumor and normal samples and pooled internal reference
standard was separately labelled with either Cy3, Cy2, or Cy5
CyDye DIGE fluors (GE Healthcare), combined, and 2D gel
electrophoresis performed (see supplementary data for more
detailed method). The pooled reference consisted of equal
amounts of every sample in the cohort. Each gel was scanned
(Typhoon 9400 Variable Mode Imager, GE Healthcare) to
produce 3 independent spot maps corresponding to the Cy2,
Cy3 and Cy labelled proteins, and the spot maps analysed
with DeCyder v5 software (GE Healthcare).
2.5. Protein Identification. A 2D preparative gel containing
150 μg of pooled unlabeled LMD tumor protein was elec-
trophoresed as before and visualised using a MS-compatible
silver stain [19]. Protein spots of interest were matched
between the analytical gels and the preparative gel, excised,
washed five times with 25mM ammonium bicarbonate/50%
acetonitrile, dehydrated with 100% acetonitrile, and digested
with 20 μL of 20 μg/mL trypsin in 25mM ammonium
bicarbonate/10% acetonitrile overnight at 37◦C. Digested
peptides were analysed using a Dionex Ultimate 3000 HPLC
(Dionex Corp, Sunnyvale, CA, USA) coupled to a Thermo
LTQ XL linear ion trap mass spectrometer fitted with a
nanospray source (Thermo Electron Corp, San Jose, CA,
USA) as previously described [20]. Peak lists were generated
with the Bioworks 3.3 software (Thermo Scientific) using the
Sequest algorithm and searched against the IPI human data
base v3.58. A correct match was assigned when the cross-
correlation scores of matches were greater than 1.5, 2.0, and
2.5 for a charge state of 1, 2, and 3 peptide ions respectively,
the peptide probability score was less than 0.001, and when 2
or more unique peptides per protein were identified.
2.6. Purification and Identification of K8 Phosphorylated
Proteins. Protein extracted from SW480 cells (750 μg) was
separated by 2DE using 24 cm pH 3–7NL IPG strips and
8–15% polyacrylamide gels as before. Gels were visualised
with Coomassie blue. The 3 K8 isoforms of interest were
individually excised from the gels and digested with trypsin
as previously described [21]. Phosphorylated peptides were
enriched using Phos-trap TitaniumDioxide (TiO2)magnetic
beads (Perkin Elmer, San Jose, CA, USA) according to the
manufacturer’s protocol.
The eluted peptide solution (1.5 μL) was spotted onto a
600 μm AnchorChip (Bruker Daltonics, Bremen, Germany)
target plate with 1 μL of 2,5-DHB (10mg/mL) matrix in
50% ACN/0.1% TFA/0.1% PA. MALDI TOF MS/MS was
carried out as previously described [21] using a Bruker
ultraflex III MALDI TOF/TOF mass spectrometer (Bruker
Daltonics). The spectra and mass lists were exported
to BioTools v3.1 (Bruker Daltonics), where the MS and
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corresponding MS/MS spectra were combined and sub-
mitted to the in-house Mascot database-searching engine
(Matrix Science). Data was matched against the SwissProt
57.1 database. In addition, an in silico digest of K8 was
performed using the sequence editor platform of BioTools to
identify potential phosphopeptides. Precursor ions suspected
to be phosphorylated peptides were chosen for MS/MS anal-
ysis. Spectra ion annotation was performed using MOWSE
and probability scores. For spectra that matched to precursor
ions of potential phosphorylated peptides, annotation was
performed using BioTools, and each phosphorylation posi-
tion was evaluated manually.
2.6.1. Confirmation of K8 Phospho-Serine Isoforms. 2D west-
ern blots of protein extracted from the CRC cell line Caco2
were performed with phospho-specific antibodies against
PS24, PS432, and PS74. Protein (300 μg) was separated by
2DE as before and transferred using a semidry apparatus
for 1 hour at 70mA per blot onto low fluorescent PVDF
membrane. Membranes were blocked in 5% skimmilk PBST,
washed, and incubated overnight at 4◦C with each of the
primary antibodies. Membranes were washed and incubated
in the dark at room temperature for 1.5 hours with ECL
Plex fluorescent detection Cy3 antibody (GE Healthcare) at
a 1 : 1000 dilution. Membranes were washed, air dried, and
imaged using a Typhoon 9400 Imager (GE Healthcare).
2.6.2. Quantification of Phospho-K8 Isoforms by Western Blot-
ting. To determine the levels of K8 and the phosphorylated
isoforms, western blotting was performed on 30 tumor and
30 matched normal mucosal samples (10 stage I, 10 stage
II, and 10 stage III cases). For protein extraction, 30 μ
cryosections were pulverised in a mortar and pestle under
liquid nitrogen and placed in 200 μL of sample buﬀer (2%
SDS, 10% glycerol, 62.5mM TrisHCl pH 6.8, 6M urea,
1x Halt phosphatase inhibitors (Sigma), 65mM DTT, and
150U Benzonase (Sigma)). Samples were purified using
the 2D Clean Up Kit (GE Healthcare), resuspended in
100 μL of sample buﬀer, and quantified using the EZQ assay
(Invitrogen). Western blotting for the 3 phospho-antibodies
was performed as before except that 50 μg of each sample
was run on 4–20% polyacrylamide gels. Unmodified K8
was also detected using a K8 antibody. A β actin loading
control antibody was included for all blots. Membranes
were incubated with ECL Plex Cy3 and Cy5 antibodies (GE
Healthcare) and imaged as before. Bands were quantified
using ImageQuant V5 software.
Levels of K8 were normalised to β actin in each sample
and the ratio of tumor to normal protein expression was
calculated. For the K8 phospho-specific antibodies, each
band was normalised to β actin, then normalised to total
K8 expression. The ratios of the level of phospho-isoforms
in tumor versus normal were calculated. Statistical analysis
was performed using GraphPad Prism 4 software.
2.7. Blocking EGFR Signaling in Caco2 Cells. The colon cell
line Caco2 (ATCC, Manassas, VA, USA) was treated with the
sc-120 antibody (Santa Cruz) to block the ligand binding
site of EGFR. Caco2 cells were plated in duplicate at 1 ×
105 cells per well in a 24-well plate in a total volume of
350 μL RPMI media with 10% FCS in humidified 5% CO2
in air. Cells were treated with 1 μg of antibody per well. This
amount was determined to be saturating by flow cytometry
(Supplementary Figure 2). Treated and untreated control
cells were harvested at 4, 6, and 8 hours after antibody
treatment by lysis in 50 μL of sample buﬀer. Lysates were
quantified and western blotting was performed on 25 μg of
each sample for K8, PS24, PS74, PS432, and a β actin loading
control as before. For the K8 phospho-specific antibodies,
each bandwas normalised to β actin, then normalised to total
K8 expression. This experiment was repeated three times and
the statistical significance of the diﬀerence between means
for each treatment time was determined by ANOVA, with
P < 0.05 being considered significant.
2.8. Apoptosis Induction of sc-120 Antibody-Treated Cells
Compared to Untreated Cells. Caco2 cells were treated with
the sc-120 antibody as before to reduce K8 PS74 and PS432
levels. Six hours after sc-120 treatment 1 μM of doxorubicin
(DOX) was added to the appropriate treatment wells as a cell
stressor. Treatments were sc120 plus DOX, sc120 alone, DOX
alone, and untreated cells. After 8 hours, cells were washed
with PBS and lysed in 50 μL of sample buﬀer. Lysates were
quantified and western blotting was performed on 50 μg of
each sample. Fluorescence intensity of bands was quantified
as before. Levels of cleaved caspase-3 were normalised to
β actin expression in each sample. This experiment was
repeated three times and the statistical significance of the
diﬀerence between means for each treatment time was
determined by ANOVA, with P < 0.05 being considered
significant.
3. Results
3.1. Laser Microdissection and Protein Extraction. To avoid
contamination from other cell types, LMD was used to
enrich for epithelial cells from matched tumor-normal
paired tissues from 8 stage II cases. The mean tumor
protein yield was 115± 29.4 μg, from an area of 47± 7.9mm2
(2.4 μg/mm2) while the mean normal mucosa protein
yield was 91± 10.1 μg, from an area of 60± 28.9mm2
(1.5 μg/mm2).
3.2. Determination of Diﬀerentially Expressed Proteins by 2D
DIGE and Mass Spectrometry. Using DeCyder v5 software,
a total of 1,745 protein spots were matched across all gels
and the tumor-normal abundance ratio of each protein spot
listed with its significance (Student’s t-test). The data set was
filtered by selecting protein spots with an average abundance
ratio of tumor to matched normal of ≥2-fold, limited
to spots matched on all gels and applying a significance
threshold of P ≤ 0.05. The protein with the highest level
of tumor upregulation was K8 and was among 25 proteins
significantly upregulated by ≥2 fold between tumor and
matched normal mucosa, identified by ion trapMS (data not
shown). Three protein spots were identified as K8, 2 spots as
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Table 1: Protein identification.
Spot IDa Acc no.b pIc MW (Da)d Xcorre No. of peptidesf % Sequence coverageg
1 K8 P05787 5.38 53672 270.2 19 39.75
2 K8 P05787 5.50 53672 230.3 16 39.13
3 K8 P05787 5.70 53672 210.3 15 34.78
4 K18 P05783 5.21 48029 100.3 9 30.39
5 K18 P05783 5.30 48029 120.2 8 31.40





dCalculated molecular weight, Daltons.
eXcorr: significance score.
fNumber of peptides sequenced.
g% of the full length protein sequence covered by identified peptides.
Table 2: Quantitative 2D DIGE data (DeCyder software).
Individual tumour-normal abundance ratios
Spot ID Ave. ratioa Pb 1 2 3 4 5 6 7 8
1 K8 4.56 0.00026 2.50 8.70 3.50 6.20 5.20 5.10 1.30 3.90
2 K8 4.36 0.0052 1.30 7.50 4.30 7.50 3.40 7.70 0.80 2.00
3 K8 3.98 0.0019 1.40 4.50 2.70 4.40 5.30 5.70 0.95 6.80
4 K18 4.22 0.013 1.20 10.50 4.40 2.00 4.60 8.50 1.60 0.80
5 K18 4.00 0.037 0.70 9.60 4.20 3.00 4.60 7.70 1.70 0.48
6 K19 2.34 0.018 0.93 4.32 1.71 2.01 1.83 4.96 0.87 2.13
a
Average tumor-normal abundance ratio.












Figure 1: A DeCyder 2D gel image displaying the keratin proteins
significantly increased in the tumors. Circled are the identified ker-
atin proteins significantly increased in the LMD tumors compared
to matched normal mucosa. The labeled protein spots in the boxed
area correlate with the data given in Tables 1 and 2.
K18, and a further spot corresponding to K19 (Figure 1 and
Table 1). All 3 K8 protein spots were increased≥2-fold in 6/8
tumors. The average tumor to normal abundance ratios for
the isoforms of K8 calculated by DeCyder software are shown
in Table 2.
3.3. Phosphorylation Site Identification. The K8 isoforms
detected as increased in tumor were excised from a prepar-
ative 2D gel and digested with trypsin. Phosphorylated
peptides were enriched using Phos-Trap TiO2 beads and sub-
jected to MALDI-TOF/TOF MS analysis. The annotated MS
spectra pre- and postbead enrichment is shown in Supple-
mentary Figure 3. Precursor ions withm/z ratios of potential
phosphopeptides were chosen for MS/MS analysis. Two pre-
cursor ions at m/z 991.378 and 3805.269 were identified in
the K8 isoforms, and matched to previously annotated phos-
phopeptides by performing an in silico digest of K8 using
the sequence editor platform of BioTools (Bruker Daltonics).
Complete y-ion sequence coverage was obtained for the
[M+H]+-ion 991.378 ([23]–[37] SYTSGPGSR), with the loss
of 80 and 98 being detected (Supplementary Figure 4). Par-
tial sequence and the mass loss of a phosphate were obtained
from the [M+H]+-ion 3805.269 ([415]−−[454] TTSGYAG-
GLS(s)A(y)GGL(t)(s)PGLSYSLGSSFGSGAGSSSFSR) (Sup-
plementary Figure 5). The residue that had lost the phos-
phate group was assigned by using BioTools, where all
possible phosphorylation sites within the peptide were
analysed and ranked according to probability. The peptide
contains 4 potential phosphorylation sites according to the
Uniprot data base (http://www.uniprot.org/uniprot/P05787)
ISRN Molecular Biology 5
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Figure 2: Levels of K8 phospho-isoforms determined by western
blotting. (a) Plots showing abundance levels of PS24, PS432,
and PS74 normalised to β actin loading control and total K8 in
30 matched pairs of tumor-normal tissues. (b) A representative
western blot of total K8, β actin and PS432. In the case of multiple
bands, all bands were included in quantification. Tumor (T) and
normal (N) pairs were loaded in adjacent lanes from left to
right. Statistical analysis was performed using a 2-tailed Wilcoxon
matched pairs test.
of which 2 have been assigned by similarity and 2 by
annotation. The serine residue 432 was scored as having the
highest probability of phosphorylation using BioTools. Using
phospho-specific antibodies, 2D western blots confirmed the
presence of the serine phosphorylated residues 24, 432, and
74 in the K8 spots of interest (Supplementary Figure 6).
3.4. Quantification of Phospho-K8 Isoforms by Western Blot-
ting. The results of western blot quantification are shown in
Figure 2(a) with a representative blot shown in Figure 2(b).
Multiple bands for K8 were detected in some samples within
the molecular weight range of 40 to 55 kDa (Figure 2(b))
indicating proteolytic cleaved forms of K8. Such proteolysis
of K8 has been previously described in CRC [22]. The range
of MW for K8 detected on western blotting was not found
on the 2D DIGE gel (Figure 1). The reason for this could
be due to either the cleaved forms resulting in a shift in
isoelectric point and so were not present in the identified









































































































Figure 3: Tumor : normal abundance ratios according to stage.
Graph shows the abundance ratio tumor (T) to matched normal
mucosa (N) for total K8 and each phospho-serine K8 isoform,
according to tumor stage. Horizontal line shows the 2-fold abun-
dance ratio T :N. There was no significant diﬀerence in the means
for each isoform abundance ratio among diﬀerent stages.
to the intact isoforms to be detected by DIGE. The median
expression level (arbitrary units) of total K8 in the tumor
samples was 2.75 compared to 1.8 in the matched normal
samples (P = 0.053 Wilcoxon signed rank test). For the
phospho-K8 isoforms the median level between the tumor
and matched normal was significantly diﬀerent: PS24 0.667
and 0.29, respectively, P = 0.004; PS432 1.02 and 0.30,
respectively, P = 0.03; PS74 0.18 and 0.06, respectively, P =
0.0005 (Wilcoxon signed rank test). Among the 30 patients,
16/30 (53%) showed overabundance (tumor : normal ratio
≥2) for PS24, 17/30 (57%) for PS432, and 19/30 (63%) for
PS74 (Figure 3).
3.5. Blocking EGFR Signaling in Caco2 Cells Decreases Levels of
PS74 and PS432. Caco2 cells, wild type for BRAF and KRAS,
were treated with the sc-120 antibody (Santa Cruz) that
blocks ligand binding and hence activation of EGFR. Treated
and untreated cell lysates were then analysed by western
blotting for PS24, PS74, and PS432. Treatment of Caco2
cells with the sc-120 antibody led to a significant decrease
in the levels of PS74 (P < 0.0001) and PS432 (P < 0.0001)
(ANOVA) at 6 and 8 hours after treatment (Figure 4). At the
4-hour time point levels of PS74 were 81.5% ± 8.8 that of the
untreated cells. At the 6 and 8 hour time points PS74 levels
had decreased to 40.7% ± 5.1 and 42.3% ± 5.3 that of the
untreated cells, respectively. Levels of PS432 were 91.7% ±
5.2 that of the untreated cells at 4 hours, and decreased
to 36.7% ± 7.5 and 34.0% ± 2.1 of the untreated cells at
the 6 and 8 hour time points, respectively. PS24 levels were
not significantly diﬀerent after treatment with the sc-120
antibody, P = 0.73.
3.6. Caco2 Cells with Decreased Levels of PS74 and PS432
Showed Increased Apoptosis Following DOX Treatment. K8
PS74 and PS432 levels were reduced by inhibition of EGFR































































































































Figure 4: Blocking EGFR signaling in Caco2 cells leads to reduction
in PS74 and PS432 levels. Caco2 cells were treated with the EGFR
ligand binding blocking antibody sc-120 for 4 hours, 6 hours, and
8 hours (n = 6 per treatment group). (a) Western blotting and
band intensity quantification was performed on the cell lysates
with antibodies against total K8, PS24, PS74, and PS432. Levels of
PS74 and PS432 were significantly reduced 6 and 8 hours after sc-
120 treatment, P < 0.0001. As expected, levels of PS24 remained
unchanged by treatment with sc-120, P = 0.73. (b) Representative
western blots: B1, PS432; B2, PS74; B3, PS24. The lower bands in
each case are the β actin loading controls.
signalling using the sc-120 anti-EGFR antibody, following
which they were treated with DOX to induce apoptosis.
Apoptosis induction was analysed by western blotting for
cleaved caspase-3. Cleaved caspase-3 levels were significantly
higher in the sc-120 antibody + DOX-treated cells (0.13 ±
0.006) compared to the DOX alone (0.11 ± 0.002), sc-
120-treated (0.081 ± 0.008) or -untreated (0.071 ± 0.006),
P = 0.0005 (ANOVA) (Figure 5). The results represent an
increase in cleaved caspase 3 levels relative to untreated cells
of 82%, 54%, and 14%, respectively.
4. Discussion
This study found K8 isoforms, CK18, and CK19 to be
significantly upregulated in laser microdissected tissue from
8 stage II tumor samples compared to matched normal by
2D DIGE. The advantage of 2D DIGE over standard 2D
gels is the greatly improved statistical validity obtained due
to the presence of the tumor, normal and pooled reference
sample, to which abundance of each spot is normalised,



















Figure 5: Apoptosis assay (cleaved caspase-3). Cleaved caspase-3
levels were significantly higher in the sc-120 + DOX-treated cells
compared to the DOX-alone, sc-120-treated, and -untreated cells,
P = 0.0005 (ANOVA).
The software uses a novel algorithm used to match spots
gel to gel and, through spot normalisation, greatly reducing
gel-gel variation eﬀects and increasing the statistical value
of results. We hypothesised that the K8 isoforms present
in abundance in the tumor samples compared to matched
normal were a result of increased phosphorylation. Indeed,
this was confirmed using mass spectrometry, bioinformatics,
and 2D western blotting. In a larger cohort of human colon
cancer tissues, levels of all 3 K8 isoforms PS24, PS432, and
PS74 were found to be significantly increased in tumor
compared to matched normal mucosa across all stages.
Mutation of genes in the EGFR signaling cascade results
in increased RAS/RAF/MEK/ERK pathway activation and
increased MAPK (ERK1/ERK2) activity in particular [23].
The kinase ERK1 is known to phosphorylate K8 serine
431 [24]. It has also been reported that ERK1 is involved
in phosphorylation of K8 at serine 73 in A549 tumor
cells in response to an apoptosis-inducing agent, as the
phosphorylation was blocked only by an ERK inhibitor [25].
We showed that blocking of the EGFR-ligand binding site in
the CRC cell line Caco2 (wild type for both KRAS and BRAF)
resulted in a significant decrease in not only K8 PS432 but
also PS74 (P < 0.0001) in support of the earlier work. The
MAP kinase p38 and JNK are also known to phosphorylate
serines 431 and 73 [10, 13], but the blocking of EGFR would
have had no direct eﬀect on the activity of these kinases.
In our study the level of K8 PS24 was significantly
increased in the tumor samples compared to matched
normal (P = 0.004). Treatment of Caco2 cells with the
sc-120 antibody did not significantly aﬀect K8 PS24 levels,
suggesting that kinases involved in the EGFR signaling
pathway are not involved in the phosphorylation of this
residue. One study has shown that protein kinase C ε
phosphorylates K8 S24 in rat pituitary cells stimulated by
thyrotropin-releasing hormone [26].
This study in colon cancer has shown that the majority of
cases show increased tumor levels of PS74, PS24, and PS432.
Decreasing the levels of PS74 and PS432 levels in Caco2
cells resulted in the cells being more susceptible to apoptosis
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induction following DOX treatment. Phosphorylation of K8
residues causes disaggregation of K8 IF, increased solubility
and intracellular redistribution [9, 27–29]. The soluble form
of K8 acts as a phosphate “sponge” inhibiting phospho-
kinase activation of proapoptotic substrates and thereby
protecting the cells from apoptosis [11]. K8 hyperphospho-
rylation at PS74 and PS432 would thus promote tumor
cell survival and progression and may be a biomarker
for colon tumors with increased resistance to apoptosis-
inducing therapeutic agents. However, longitudinal studies
in a larger patient cohort are needed to address this point.
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